Hyasynth Archives - Green Market Report

William SumnerMay 24, 2018
Organigram-Holdings.jpg?fit=960%2C540&ssl=1

3min1010

Organigram Holdings Inc. (OGI) announced today that it has entered into a non-binding letter of intent with Hyasynth Biologicals Inc. Hyasynth is a biotechnology company that captured headlines several years ago with news that the company was capable of producing phytocannabinoids using genetically engineered strains of yeast; which allows the company to manufacture CBG, CBD, and THC for novel and specialized products, and as pharmaceutical ingredients.

Hyasynth was recently awarded by Health Canada a dealer’s license, which will allow Hyasynth to expand its operations beyond research and into commercial production

Under the LOI, Organigram will make a strategic investment in Hyasynth. The LOI also includes the possibility of Organigram entering into an off-take agreement with Hyasynth, in which Organigram could purchase a pre-defined quantity of a range of cannabinoids or cannabinoid-related production from Hyasynth.

Once the strategic investment is finalized, Organigram will have the right to purchase up to $10 million senior secured convertible debentures of Hyasynth, which would be completed in a series of three rounds. The second and third round would be contingent on Hyasynth attaining certain milestones.

Provided that Organigram engages in all three rounds the outstanding debt under the debentures would be converted into equity shares in Hyasynth which, if fully converted, would represent a considerable interest in the company. Additionally, Organigram will be granted certain investor rights and board representation.

“As a proven technology the use of bioreactors is an infinitely scalable process which should allow Hyasynth to produce pharmaceutical grade cannabinoids at a significantly lower cost than traditional plant-based production, which has numerous medical and adult recreational use applications,” said Organigram CEO, Greg Engel, in a statement. “The funding provided by Organigram will allow Hyasynth to refine and optimize its processes at scale via a contract manufacturer as well as fund a purpose-built manufacturing facility for production and also provides Organigram with the ability to purchase up to 25% of the cannabinoids produced by Hyasynth.”


Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 37 mins

Slang Losses Trend Down, Still Not Profitable

@GreenMarketRpt – 2 hours

Organigram Posts Record Revenues in Q4, Predicts More Growth in 2023

@GreenMarketRpt – 3 hours

RIV Capital Closing in on New York Acquisition, Loses $142 Million in Q2

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

By continuing I agree to your Privacy Policy and consent to receive relevant newsletters and other email communications on events, editorial features, and special partner offers from Green Market Report. I can unsubscribe or change my email preferences at any time.